CNBC’s Angelica Peebles and Novo Nordisk CEO Lars Fruergaard Jørgensen join 'Squawk Box' to discuss the company's quarterly ...

Celebrities' use of weight loss drugs like Ozempic and Wegovy has surged, including Sharon Osbourne and Elon Musk. However, users report severe side effects such as erectile dysfunction and reduced ...

Novo's earnings results Wednesday differ from Eli Lilly's, whose stock slid on slower-than-expected sales of weight loss ...

By Maggie Fick and Stine Jacobsen LONDON/COPENHAGEN (Reuters) -Obesity drug maker Novo Nordisk forecast slower growth this ...

Novo Nordisk (NYSE:NVO) forecasted slower sales growth for 2025, reflecting an expected moderation in demand for its ...

The weight-loss drugmaker's Wegovy and Ozempic are among the most closely watched new medications in recent history, but face serious competition from Eli Lilly’s Zepbound and Mounjaro.

The use of blockbuster weight loss drugs has surged among young women, for whom the treatments can often be "liberating." ...

Novo Nordisk reported Q4 sales of $11.96 billion, beating estimates. The company plans a new phase 3 trial for CagriSema in ...

Novo Nordisk (NVO) said on Wednesday that its emissions rose by nearly a quarter in 2024 and will continue to increase up to ...

Wegovy maker Novo Nordisk is not immune to tariffs U.S. President Donald Trump is threatening to levy on the European Union, ...

Novo Nordisk, maker of the weight-loss drug Wegovy, faces potential challenges as U.S. President Trump threatens tariffs on ...

Wegovy maker Novo Nordisk on Wednesday forecast sales would grow at a slower rate this year although the outlook was roughly ...